Nhc Healthcare, Moulton | |
300 Hospital Street, Moulton, Alabama 35650 | |
(256) 974-1146 | |
Name | Nhc Healthcare, Moulton |
---|---|
Location | 300 Hospital Street, Moulton, Alabama |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 136 |
Occupancy Rate | 65.66% |
Medicare ID (CCN) | 015128 |
Legal Business Name | Nhc Healthcare-moulton Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1639104235 |
Organization Name | NHC HEALTHCARE-MOULTON LLC |
Address | 300 Hospital St, Moulton, AL 35650 |
Phone Number | 256-974-1146 |
News Archive
A new study published on the medRxiv* preprint server used automated high content immunofluorescence microscopy (AHCIM) to assess the viability of such an approach to detect humoral immune responses against SARS-CoV-2 proteins.
TE Connectivity Ltd., a world leader in connectivity, announced today that it has entered into a definitive agreement to acquire AdvancedCath for $190 million USD in cash.
Antiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Tanabe Research Labs USA, Inc. (TRL) today announced commencement of its new operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases. TRL began its new activities in May with the appointment of three new senior executives: Masaki Yamada, Ph.D., Chief Executive Officer; Toshihiro Hosaka, Ph.D., Senior Vice President, and Roland Newman, Ph.D., VP and Chief Scientific Officer.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A new study published on the medRxiv* preprint server used automated high content immunofluorescence microscopy (AHCIM) to assess the viability of such an approach to detect humoral immune responses against SARS-CoV-2 proteins.
TE Connectivity Ltd., a world leader in connectivity, announced today that it has entered into a definitive agreement to acquire AdvancedCath for $190 million USD in cash.
Antiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Tanabe Research Labs USA, Inc. (TRL) today announced commencement of its new operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases. TRL began its new activities in May with the appointment of three new senior executives: Masaki Yamada, Ph.D., Chief Executive Officer; Toshihiro Hosaka, Ph.D., Senior Vice President, and Roland Newman, Ph.D., VP and Chief Scientific Officer.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 25.18 | 14.46 |
Percentage of long-stay residents who lose too much weight | 0.76 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 66.15 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.89 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 7.31 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 7.62 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.15 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.46 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 23.23 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.08 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 4.85 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 41.56 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.18 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 8.24 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 94.75 | 95.98 |
Percentage of short-stay residents who made improvements in function | 73.4 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 84.77 | 82.93 |
News Archive
A new study published on the medRxiv* preprint server used automated high content immunofluorescence microscopy (AHCIM) to assess the viability of such an approach to detect humoral immune responses against SARS-CoV-2 proteins.
TE Connectivity Ltd., a world leader in connectivity, announced today that it has entered into a definitive agreement to acquire AdvancedCath for $190 million USD in cash.
Antiretroviral therapy (ART) for infants born with HIV infection may be most effective when given in their first five months of life, according to a study published in the April 1 issue of The Journal of Infectious Diseases.
Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.
Tanabe Research Labs USA, Inc. (TRL) today announced commencement of its new operations at the TRL facility in San Diego with a focus on biological drugs for the treatment of autoimmune diseases. TRL began its new activities in May with the appointment of three new senior executives: Masaki Yamada, Ph.D., Chief Executive Officer; Toshihiro Hosaka, Ph.D., Senior Vice President, and Roland Newman, Ph.D., VP and Chief Scientific Officer.
› Verified 8 days ago